• Consensus Rating: Buy
  • Consensus Price Target: $13.25
  • Forecasted Upside: 301.52%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.30
▲ +0.01 (0.30%)

This chart shows the closing price for CRMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CorMedix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRMD

Analyst Price Target is $13.25
▲ +301.52% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for CorMedix in the last 3 months. The average price target is $13.25, with a high forecast of $19.00 and a low forecast of $10.00. The average price target represents a 301.52% upside from the last price of $3.30.

This chart shows the closing price for CRMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in CorMedix. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/31/2024Truist FinancialLower TargetBuy ➝ Buy$18.00 ➝ $14.00Low
11/15/2023Truist FinancialReiterated RatingBuy ➝ Buy$18.00Low
11/15/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$6.00 ➝ $10.00Low
11/15/2023Needham & Company LLCLower TargetBuy ➝ Buy$12.00 ➝ $10.00Low
11/15/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$19.00Low
8/10/2023Royal Bank of CanadaInitiated CoverageOutperform$6.00Low
8/8/2023Needham & Company LLCLower TargetBuy ➝ Buy$13.00 ➝ $12.00Low
5/19/2023JMP SecuritiesBoost Target$16.00 ➝ $19.00Low
3/31/2023Needham & Company LLCReiterated RatingBuy$13.00Low
3/31/2023JMP SecuritiesReiterated RatingMarket Outperform$16.00N/A
3/3/2023Needham & Company LLCReiterated RatingBuy$13.00Low
3/1/2023JMP SecuritiesBoost TargetMarket Perform$14.00 ➝ $16.00Low
11/11/2022Needham & Company LLCBoost TargetBuy$12.00 ➝ $13.00Low
8/12/2022Truist FinancialLower TargetBuy$27.00 ➝ $16.00N/A
8/9/2022Needham & Company LLCLower Target$20.00 ➝ $12.00N/A
8/9/2022JMP SecuritiesLower TargetMarket Outperform$19.00 ➝ $14.00N/A
3/30/2022JMP SecuritiesReiterated RatingBuy$19.00N/A
3/18/2022JMP SecuritiesReiterated RatingBuy$19.00N/A
10/21/2021JMP SecuritiesReiterated RatingBuy$19.00N/A
10/5/2021JMP SecuritiesReiterated RatingBuy$19.00N/A
8/24/2021JMP SecuritiesReiterated RatingBuy$22.00N/A
5/14/2021Needham & Company LLCLower TargetBuy$31.00 ➝ $29.00N/A
3/31/2021Truist FinancialLower Target$30.00 ➝ $27.00N/A
3/2/2021B. RileyReiterated RatingBuy$25.00 ➝ $13.50N/A
2/17/2021Needham & Company LLCInitiated CoverageBuy$31.00N/A
2/9/2021B. RileyBoost Target$11.00 ➝ $25.00N/A
11/19/2020HC WainwrightReiterated RatingBuyN/A
9/29/2020JMP SecuritiesInitiated CoverageMarket Outperform$22.00High
9/21/2020Truist FinancialInitiated CoverageBuy$20.00High
8/25/2020HC WainwrightReiterated RatingBuy$10.00N/A
8/11/2020HC WainwrightLower TargetBuy$14.00 ➝ $10.00N/A
7/9/2020HC WainwrightReiterated RatingBuyN/A
5/12/2020B. RileyBoost TargetBuy$10.00 ➝ $12.00N/A
3/18/2020B. RileyLower TargetBuy$15.00 ➝ $10.00N/A
3/18/2020HC WainwrightReiterated RatingBuy$14.00N/A
2/4/2020HC WainwrightReiterated RatingBuy$14.00N/A
12/18/2019B. RileyReiterated RatingBuyMedium
12/18/2019B. RileyInitiated CoverageBuy$48.00N/A
12/2/2019HC WainwrightReiterated RatingBuy$14.00N/A
5/28/2019HC WainwrightSet TargetBuy$14.00N/A
3/18/2019HC WainwrightSet TargetBuy$15.00N/A
(Data available from 2/21/2019 forward)

News Sentiment Rating

1.23 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2023
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2023
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2023
  • 1 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/23/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2024
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2024

Current Sentiment

  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
CorMedix logo
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Read More

Today's Range

Now: $3.30
Low: $3.29
High: $3.31

50 Day Range

MA: $3.38
Low: $2.94
High: $3.92

52 Week Range

Now: $3.30
Low: $2.57
High: $6.09

Volume

11,595 shs

Average Volume

392,890 shs

Market Capitalization

$180.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.79

Frequently Asked Questions

What sell-side analysts currently cover shares of CorMedix?

The following equities research analysts have issued stock ratings on CorMedix in the last twelve months: JMP Securities, Needham & Company LLC, Royal Bank of Canada, and Truist Financial Co..
View the latest analyst ratings for CRMD.

What is the current price target for CorMedix?

4 Wall Street analysts have set twelve-month price targets for CorMedix in the last year. Their average twelve-month price target is $13.25, suggesting a possible upside of 302.7%. JMP Securities has the highest price target set, predicting CRMD will reach $19.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $10.00 for CorMedix in the next year.
View the latest price targets for CRMD.

What is the current consensus analyst rating for CorMedix?

CorMedix currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRMD will outperform the market and that investors should add to their positions of CorMedix.
View the latest ratings for CRMD.

What other companies compete with CorMedix?

How do I contact CorMedix's investor relations team?

CorMedix's physical mailing address is 300 CONNELL DRIVE SUITE 4200, BERKELEY HEIGHTS NJ, 07922. The company's listed phone number is (908) 517-9500 and its investor relations email address is [email protected]. The official website for CorMedix is www.cormedix.com. Learn More about contacing CorMedix investor relations.